GI focus Expands potential collaboration with GI-focused payer and provider networks, leveraging Salix’s strong pipeline in hepatic encephalopathy, IBS with diarrhea, opioid-induced constipation, and ulcerative colitis to target gastroenterology clinics, hospitals, and specialty pharmacies.

Strategic partnerships Recent alliances with patient advocacy groups and organizations (IFFGD, U.S. Pain Foundation, Chronicon) indicate readiness for co-branded education and awareness initiatives that can open access channels and advocacy-driven referral opportunities.

Sustainability tie‑ins Collaborate with Net Zero and energy initiatives to position Salix as a socially responsible partner, creating opportunities for joint sustainability programs, patient access campaigns, and potential grant-supported research collaborations.

Growth potential Revenue band and funding scale suggest the ability to pursue co-development or regional expansion partnerships, including joint venture discussions or licensing deals in additional GI indications and related supportive care products.

Risk and IP Active litigation and enforcement posture signals a need for risk-aware partnerships, focusing on strong IP due diligence, territory protections, and collaboration frameworks that minimize litigation exposure while expanding market reach.